^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CHS-114

    i
    Associations

    News

    Trials
    Company:
    Coherus Biosci
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    6d
    SRF114-101: Study of CHS-114 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=87, Recruiting, Coherus Biosciences, Inc. | N=47 --> 87
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • CHS-114
    5ms
    A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Coherus Biosciences, Inc.
    New P1 trial
    |
    Loqtorzi (toripalimab-tpzi) • CHS-114
    1year
    Study of CHS-114 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=47, Recruiting, Coherus Biosciences, Inc. | Phase classification: P1/2 --> P1 | N=70 --> 47
    Phase classification • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    CHS-114
    over1year
    Anti-CCR8 antibody CHS-114 (SRF114) depletes tumor-infiltrating regulatory T cells in dissociated tumors from patients with head and neck squamous cell carcinoma (SITC 2023)
    Molecular epidemiology studies highlight HNSCC as a tumor type with a high prevalence of CCR8+ itTregs to evaluate the anti-tumor activity of an anti-CCR8 antibody. CHS-114 (SRF114) is currently being evaluated in a Phase 1 clinical trial (NCT05635643).
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    CCR8 expression • FOXP3 expression
    |
    CHS-114
    2years
    Study of SRF114 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Surface Oncology | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    CHS-114
    over2years
    Study of SRF114 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Not yet recruiting, Surface Oncology
    New P1/2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    CHS-114